6 Of Goldman Sachs Top 2024 Stock Picks Also Pay Big Dividends Chris Hondros / Getty Images The Artificial Intelligence rally over the last year, led by the so-called “Magnificent 7,” has been fantastic if you owned those stocks. However, most of the S&P 500 is treading water and will not likely ever catch up to the hype-driven AI stocks soon.With the market trading at all-time highs, investors will likely be lured into a false sense of financial security. The reality is the United States could be set for ...

The board of directors of General Dynamics today declared a regular quarterly dividend of $1.42 per share on the company's common stock, payable May 10, 2024, to shareholders of record on April 12, 2024. This is the 27th consecutive annual dividend increase authorized by the General Dynamics board and represents a 7.6% increase over last year's dividend.10 mREITs With Impressive Yields »Amgen today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The ...

THOUSAND OAKS, Calif., March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024, to all stockholders of record as of the close of business on May 17, 2024. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This a ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's largest biotech drugmaker have returned -12.5% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 1% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

业绩总结 - Amgen公司在2023年的Repatha和EVENITY产品均实现了强劲的销量增长，分别为37%和44%[1] - TEZSPIRE在2023财年实现了5.67亿美元的销售额，覆盖率扩大至80%[1] - Amgen预计2023年第一季度的产品销售额将较上年同期增长20%，达到61亿美元[3] 新产品和新技术研发 - MariTide是一种针对肥胖症的新型药物，临床试验显示在12周内可实现14.5%的体重减轻[2] - Amgen的新药Olpasiran在心血管结局试验中已快速招募了7000多名患者[2] - Amgen计划在2024年推出多个潜在的首创或最佳类药物，包括MariTide和Olpasiran[3] 市场扩张和并购 - Horizon交易预计在第三年实现至少5亿美元的前税成本协同效应[3] 未来展望 - TEZSPIRE正在研究多种额外适应症，预计在今年上半年公布COPD数据[2] - TEZSPIRE将在下半年发布Phase II COPD数据和Phase III慢性鼻窦炎伴鼻息肉数据[7] 其他新策略和有价值的信息 - Amgen的稀有病业务以TEPEZZA、KRYSTEXXA、UPLIZNA和TAVNEOS为核心，已在沙特阿拉伯获得批准[1] - MariTide认为其药物是治疗肥胖症的重要分子，相应的体重减少效果稳定且可复制[5] - Sjögren综合征的治疗方案包括dazodalibep，这是一种CD40配体拮抗剂，可能对患者产生实质性改善[8]

Amgen (AMGN) ended the recent trading session at $279.35, demonstrating a -0.35% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.12%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.41%.Prior to today's trading, shares of the world's largest biotech drugmaker had lost 13.26% over the past month. This has lagged the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83% in that time.The upcoming ...

大型科技公司和制药公司 - 大型科技公司和制药公司都依赖于市场炒作和FDA批准来提高估值[1] - 不是所有制药公司都能保持高增长承诺，投资者需要谨慎选择要出售的制药股票[1] Eli Lilly - Eli Lilly的股价在过去一年中增长了135%，但其药物Humalog和Trulicity的销售额却有所下降[4] - Eli Lilly的市盈率在2023年为121.76，预计到2025年将下降至45.81[6] Amgen - Amgen的营收在2023年达到了82亿美元，全年增长了7%[9] - Amgen的Prolia和Enbrel药物销售额达到77亿美元，但公司的运营利润率和自由现金流都有所下降[11] BioNTech - BioNTech在与辉瑞合作推出C-19疫苗后，股价在一年内下跌了30%[13] - BioNTech在2023年第四季度的营业收入为12.7亿美元，较去年同期的22亿美元有所下降[14]

制造工厂建设 - Amgen宣布在俄亥俄州中部开设了最先进的制造工厂，名为Amgen Ohio，将为全球严重疾病提供创新生物药品[1] - Amgen Ohio将雇佣400名全职员工，设有开放式工作空间以促进合作，并致力于实现2027年所有运营的碳中和目标[2] 制造学徒项目 - Amgen与哥伦布州立社区学院合作，为新人提供为期18个月的制造学徒项目，旨在为没有正规学士学位的技术人员提供机会[3]

生物技术行业投资 - 生物技术行业投资有风险，但也有投资优势[1] CRISPR Therapeutics与Vertex Pharmaceuticals合作 - CRISPR Therapeutics获得了第一个产品Casgevy的批准，与生物技术巨头Vertex Pharmaceuticals合作开发[2] Axsome Therapeutics的产品销售增长 - Axsome Therapeutics在过去三年中取得了显著的临床和监管进展[5] - Axsome Therapeutics的产品Auvelity和Sunosi的销售额不断增长[6]

稀有疾病业务部门 - Amgen公司举行了稀有疾病投资者分析师电话会议[1] - 稀有疾病是Amgen的第四个并且是最新的长期增长支柱，对公司的长期增长具有积极影响[3] - Amgen致力于提供高度差异化的治疗方案，以满足未满足的医疗需求[8] - Amgen的稀有疾病业务部门建立在创新基础之上，拥有四种处于生命周期早期的药物，以及一系列超稀有疾病药物[13][14] 稀有疾病患者挑战 - 稀有疾病患者面临着诊断困难、治疗延迟、有限的治疗选择和地理障碍等挑战[19][20] - 稀有疾病患者的需求是独特的，需要定制和多方面的方法来解决[23][24][25] - 稀有疾病患者的诊断过程复杂，平均需要近五年时间和七个以上的专家才能得到准确诊断[25] - 稀有疾病患者面临着许多获取治疗的障碍，需要不同于常见疾病的方法来帮助他们[26] - 稀有疾病患者常常感到孤立和孤独，因此建立社区对他们和家人来说非常重要[27][28] TEZSPIRE治疗产品 - 公司的首席医疗官介绍了针对甲状腺眼病的治疗产品TEZSPIRE的机制和临床效果[30][31][32][33][34][35][36][37][38][39] - TEZSPIRE在治疗甲状腺眼病患者中取得了显著的临床效果，包括减轻眼球突出和改善其他症状[38][39] - TEZSPIRE对高和低临床活动评分的甲状腺眼病患者都有显著的疗效，且在治疗过程中持续改善[39][40] KRYSTEXXA治疗产品 - KRYSTEXXA用于难治性痛风的管理，该疾病对多个器官系统产生影响，包括慢性肾脏病和高血压[59][60][61] - KRYSTEXXA是一种聚乙二醇化尿酸酶，能够将不溶性尿酸转化为可溶性尿酸酐，从而可以迅速并轻松地从体内排出[62][63] - KRYSTEXXA在临床试验中显示，70%的患者能够将血尿酸浓度降低到每分升不到6毫克，这一结果证明了其临床有效性[64] UPLIZNA治疗产品 - 公司计划在欧洲市场推广UPLIZNA，预计有大约8,000至10,000名潜在患者[81][82] - UPLIZNA在IGg-4相关疾病和重症肌无力等新适应症方面有潜力，公司正在进行第三阶段的随机、安慰剂对照试验[87][93][97] 新药研发 - 公司正在推进多项临床研究，以提供新的罕见病治疗选择[124] - 公司正在积极推进三个潜在的治疗方案，包括dazodalibep、daxdilimab和fipaxalparant，这些方案在早期试验中显示出有希望的结果[125]